426834-38-0

Basic information

• Product Name: NS 3694
• Synonyms: Apoptosis Inhibitor II, NS3694
• CAS NO: 426834-38-0
• Molecular Formula: C15H10ClF3N2O3
• Molecular Weight: 358.702
• Product Categories: Apoptosis Inhibitors
• Mol File: 426834-38-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 378.448°C at 760 mmHg
• Flash Point: 182.679°C
• Appearance: /solid
• Density: 1.574g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.638
• Storage Temp.: 2-8°C
• Solubility: DMSO: 22 mg/mL, soluble
• CAS DataBase Reference: NS 3694(CAS DataBase Reference)
• NIST Chemistry Reference: NS 3694(426834-38-0)
• EPA Substance Registry System: NS 3694(426834-38-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 426834-38-0(Hazardous Substances Data)

Usage

Description

NS 3694 is a cell-permeable diarylurea compound that acts as a suppressor of apoptosome Apaf-1 formation. It is involved in the inhibition of caspase activation, which plays a crucial role in the regulation of apoptosis in cells.

Uses

Used in Pharmaceutical Industry:
NS 3694 is used as a therapeutic agent for the inhibition of apoptosome formation and caspase activation. Its application is particularly relevant in the study and treatment of conditions involving dysregulated apoptosis, such as certain cancers and neurodegenerative diseases.
Used in Research Applications:
NS 3694 is used as a research tool to examine the role of apoptosome-mediated caspase activation in cell death. It helps researchers understand the molecular mechanisms underlying apoptosis and identify potential targets for therapeutic intervention.
Used in Cancer Treatment:
NS 3694 is used as a potential therapeutic agent in cancer treatment, as it prevents the formation of apoptosomes, which are involved in the activation of caspases and subsequent cell death. By inhibiting this process, NS 3694 may help in the development of novel strategies to combat cancer progression and improve patient outcomes.

in vitro

previous study found that ns3694, and its two analogs (ns1764 and ns1784) were well-tolerated by mcf-7s1 breast cancer cells at concentrations up to 100, 50, and 25 μm, respectively. moreove, all three compounds could not inhibit recombinant caspase 9 and caspase 3 at concentrations ranging from 25 to 100 μm. in addition, ns3694 was able to inhibit the co-immunoprecipitation of caspase 9 and apaf-1 from hela cell cytosol stimulated by cytochrome c and datp. ns3694 could also inhibit the formation of the active 700-kda apoptosome complex, but had no effect on tnf-induced caspase-independent death of wehi-s cells. ns3694 did not inhibit fasl-induced caspase activation or death in type i cells neither [1].

IC 50

approximately 50 μm for cytochrome c-induced caspase activation in hela cell cytosolic extracts

references

[1] lademann, u. ,cain, k.,gyrd-hansen, m., et al. diarylurea compounds inhibit caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex. mol.cell biol. 23(21), 7829-7837 (2003).

InChI:InChI=1/C15H10ClF3N2O3/c16-9-4-5-11(13(22)23)12(7-9)21-14(24)20-10-3-1-2-8(6-10)15(17,18)19/h1-7H,(H,22,23)(H2,20,21,24)

Upstream product

• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 329-01-1 1-isocyanato-3-trifluoromethyl-benzene 

Relevant articles and documents

NOVEL ARYL UREIDO BENZOIC ACID DERIVATIVES AND THEIR USE

This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.